SCI Floor Covering, backed by Ranier Capital, is expanding through strategic acquisitions in the Midwest. Despite some market softness, SCI President and CEO Dave Elberson remains optimistic about the flooring industry's outlook. Learn about his acquisition strategy, business outlook and SCI's career path for installers. 

The National Floorcovering Alliance (NFA) members demonstrated classic American entrepreneurial resilience at their fall meeting in Washington, D.C., October 27-30, reporting flat to positive business performance in 2024 despite broader market softness.

The International Union of Painters and Allied Trades (IUPAT) is constantly working with industry leaders to maintain information and training about safety practices and updates on safety equipment on construction sites. Here, they share more about their practices to keep you safe on the jobsite. 

Floor Trends & Installation Managing Editor Beth Miller shares her experience attending the International Certified Flooring Installers (CFI) Association LVP, Laminate, and Hardwood Technical Certification alongside the Mohawk and Performance Accessories product teams at the Mohawk Training Facility in Dalton, Georgia.  

The ASTM F06 Committee approved a new standard that covers single-component fluid-applied moisture mitigation systems for use under resilient flooring installed on concrete substrates.

Food Engineering has revamped its schedule of most prominent annual features. Casey Laughman shares some of those changes as we kick off 2021.

Coval Technologies, an innovator in covalent bonding spray down coating systems, introduces the Coval SP-HV industrial sprayer.

The newest flooring accessories for 2023 check all the boxes: they are great looking, easier to install, and have better functionality than ever before. 

Two new ANSI gauged porcelain/thin tile standards were announced at Coverings 2017.

Donato Pompo earned the top prize for Coverings Advocate Leader at Coverings 2017.

Coverings, the largest showcase of ceramic tile and natural stone in North America, has announced Coverings 2025 registration with early-bird registration perks, competitive hotel rates and award opportunities.

Children's Geographies; 06/01/2023
(AN 164286255); ISSN: 14733285
Academic Search Premier

The post British criminology, undercover policing, and racist attacks: Notes on the ‘law and order’ information infrastructure was curated by information for practice.

The post A person-centred conceptualisation of non-suicidal self-injury recovery: a practical guide was curated by information for practice.

The post Suicide Screening and Care Help Lead to Recovery was curated by information for practice.

Disaster SNAP (D-SNAP) and other federal nutrition programs play a critical role in mitigating spikes in food insecurity during such challenging times. This is due to their ability to expedite and strengthen the response to disasters of various types.

The post Leveraging Federal Nutrition Resources for Disaster Recovery was curated by information for practice.

The post The How and Why of Recovery of Grant Funds was curated by information for practice.

Sustained financing for Universal Health Coverage (UHC) has been a concern for the Cameroon government. Household contributions have been considered as a financing mechanism, but this raises concerns on the wi… Read the full article ›

The post Factors associated with household willingness to pay for Universal Health Coverage in Cameroon: a nationwide cross-sectional analysis was curated by information for practice.

The post Machine Learning Technology in Predicting Relapse and Implementing Peer Recovery Intervention Before Drug Use Occurs was curated by information for practice.

Clouds will be thickening Saturday night, with rain showers developing late. Expect rainy conditions on Sunday, with temperatures hovering above the seasonal average of 50 degrees.

Last Thanksgiving, Eliana Szabo suffered a brain hemorrhage when an arteriovenous malformation ruptured. Now 11, she has relearned how to walk and talk. Meanwhile, a fellow pianist is trying to raise $10,000 through selling handmade paper cranes.

An archaeological team’s excavation of an ancient city has uncovered “surprising” revelations about an early Christian church in Egypt, specifically, the discovery of 17 human remains and the story the bodies tell.

Archbishop of Canterbury Justin Welby, leader of the Church of England and the global Anglican Communion, has announced that he will be resigning amid outrage over an abuse cover-up scandal.

Known to millions as the drummer of the Grammy Award-winning band Hootie & the Blowfish, Jim “Soni” Sonefeld once appeared to have it all — a successful career, a loving family and a public image that masked his private struggles. Beneath the surface, however, he grappled with inner demons.

More than 100 tons of gold were found on Sovinoye deposit in Chukotka (a region in the Far East of Russia). This is the largest deposit to have been discovered since the collapse of the USSR in 1991, Atomredmetzoloto Company (ARMZ), a mining division of Rosatom state corporation said. Drilling operations were carried under continuous permafrost conditions all the year round, the company said. In just three years, 123 wells were drilled (more than 32 km in total). At the moment, all prospecting, topographic-geodetic, geological-geochemical and geophysical works on the deposit have been completed. Rosatom invested more than 1 billion rubles to create a mining cluster based on the Sovinoye deposit. The project provides for the creation of an industrial complex for the extraction and processing of gold ores with the further production of alloyed gold bars.

Astronomers at the University of Warsaw in Poland discovered a new Cepheid variable star. The newly discovered star, designated OGLE-GD-CEP-1884, has the longest pulsation period known for any variable of its type in the Milky Way Galaxy, an article published on the arXiv preprint server says. Cepheids are yellow giant and supergiant stars that change their brightness over time as a result of regular stellar pulsations. Given that their pulsation periods are closely related to their luminosity, astronomers use these stars to measure interstellar and intergalactic distances. Classic Cepheids, also known as Type I Cepheids, pulsate with highly regular periods ranging from a few days to months.

The big loser in the French elections was not the far right. It's true that if it hadn't been for the spurious agreements between the New Popular Front and the Macronists, the National Regroupment would have grown even more. But the result of the second round is not exactly a victory for the left. After Marine Le Pen's RN led the first round of the elections, the leaders of the NFP fell into the trap of the French press and Emmanuel Macron, abandoning numerous candidates of their own to increase the chances of the neoliberal right linked to the Renaissance party beating the far right.  The French big bourgeoisie called for a "republican front" to create a "cordon sanitaire" made up of the left and the neoliberal right in order to prevent a landslide victory for the RN, which led to agreements in around 220 constituencies for the candidate with supposedly the least chance of winning the RN to abandon the race in favour of the candidate with the greatest chance. Except that most of the abandonments were by the NFP so that Macron's allies could beat Le Pen's allies, even though the NFP came second in the first round, far ahead of Macron's coalition.

Offering insights into the most effective, tried and tested approaches to managing retail risk, supplier of loss prevention solutions and retail technology, Checkpoint Systems UK, has revealed the conference agenda for its upcoming appearance as title sponsor at Retail Risk London on 22 July 2021.

Added September 28, 2006: The Discovery Institute selectively quotes Judge Jones' decision in Kitzmiller v. Dover Area School District in aid of its "bait and switch" claim of scientific evidence in support of intelligent design.

Added October 9, 2006: The newest addition to the Quote Mine Project shows how Casey Luskin of Discovery Institute misrepresents what Gould and others wrote in a brief for Daubert v. Merrell Dow Pharmaceuticals.

These miniature immune system models -- known as human immune organoids -- mimic the real-life environment where immune cells learn to recognize and attack harmful invaders and respond to vaccines. Not only are these organoids powerful new tools for studying and observing immune function in cancer, their use is likely to accelerate vaccine development, better predict disease treatment response for patients, and even speed up clinical trials.

A research team has identified 2,586 orphan genes (OGs) in Rosa chinensis, offering new insights into the role of these unique genes in flower development, stress response, and environmental adaptation.

These miniature immune system models -- known as human immune organoids -- mimic the real-life environment where immune cells learn to recognize and attack harmful invaders and respond to vaccines. Not only are these organoids powerful new tools for studying and observing immune function in cancer, their use is likely to accelerate vaccine development, better predict disease treatment response for patients, and even speed up clinical trials.

A research team has identified 2,586 orphan genes (OGs) in Rosa chinensis, offering new insights into the role of these unique genes in flower development, stress response, and environmental adaptation.

P1Harmony is set to release a best-hits album in Japan.According to the six-member boy group's agency FNC Entertainment on Friday, 'Love & P1ece : The Best of P1Harmony' will be released on August 21. It...

[more...]

s Virgo and Capricorn compatibility strong? Discover how these earth signs connect in love, friendship, and marriage with shared values, loyalty, and mutual support.

Discover the unique traits of each zodiac element—fire, earth, air, and water. Uncover how these elements shape personalities and compatibility in astrology.

Discovering Geology: climate change  British Geological Survey

This study proposes an operation optimization framework for impurity-free recycling of spent lithium-ion batteries. Using a hybrid population balance equation integrated with a data-driven condition classifier, the study firstly identifies the optimal batch and semi-batch operation conditions that significantly reduce the operation time with 100% purity of product; detailed guidelines are given for industrial applications.

Structure-based drug design is highly dependent on the availability of structures of the protein of interest in complex with lead compounds. Ideally, this information can be used to guide the chemical optimization of a compound into a pharmaceutical drug candidate. A limitation of the main structural method used today – conventional X-ray crystallography – is that it only provides structural information about the protein complex in its frozen state. Serial crystallography is a relatively new approach that offers the possibility to study protein structures at room temperature (RT). Here, we explore the use of serial crystallography to determine the structures of the pharmaceutical target, soluble epoxide hydro­lase. We introduce a new method to screen for optimal microcrystallization conditions suitable for use in serial crystallography and present a number of RT ligand-bound structures of our target protein. From a comparison between the RT structural data and previously published cryo-temperature structures, we describe an example of a temperature-dependent difference in the ligand-binding mode and observe that flexible loops are better resolved at RT. Finally, we discuss the current limitations and potential future advances of serial crystallography for use within pharmaceutical drug discovery.

Source: Streetwise Reports 10/18/2024

Aero Energy Ltd. (AERO:TSXV; AAUGF:OTC; UU3:FRA) has announced significant advancements at its Murmac and Sun Dog uranium projects in Northern Saskatchewan, with the first drill program revealing high-grade uranium potential. Situated near Uranium City on the Athabasca Basin's northern margin, the projects aim to capitalize on basement-hosted uranium deposits similar to high-grade discoveries in the region.

The initial drill campaign completed 16 holes, targeting 12 key areas, with 12 holes yielding anomalous radioactivity. A major highlight is the new high-grade uranium discovery in drill hole M24-017, which intersected 8.4 meters of mineralization at 0.3% U3O8, including assays peaking at 13.8% U3O8 at just 64 meters below surface. The results confirm Aero's exploration model, which focuses on basement-hosted deposits within graphitic structures, a common feature in Athabasca Basin uranium deposits like Arrow and Triple R.

"From the launch of the company in January, we took a very diligent yet aggressive approach to discovery," stated Galen McNamara, CEO of Aero Energy. "The combination of historical data and the results from the first drill program serve as evidence that basement-hosted mineralization akin to the large deposits beneath and adjacent to the Athabasca Basin is present in the area."

The Murmac project spans 25,607 acres and holds a production legacy of approximately 70 million pounds of U3O8. Similarly, the 48,443-acre Sun Dog property hosts the historic Gunnar uranium mine, which once held the title of the world's largest uranium producer. Past exploration focused on fault-hosted mineralization, missing the basement-hosted uranium potential that Aero's recent findings have validated.

Recent exploration efforts included a VTEM Plus survey, flown over 3,350 kilometers, identifying graphite-rich rocks that support Aero's exploration thesis. Additionally, two new occurrences of strong radioactivity were identified at surface-level scout locations: Target A15 showed 60,793 counts per second, and Target P4 displayed 13,533 counts per second. Summer 2024 drilling included 1,550 meters at Murmac and 1,600 meters at Sun Dog, highlighting shallow, high-grade potential in both areas.

In parallel, Aero Energy has announced a CA$2.5 million non-brokered private placement to support further exploration. The proceeds from flow-through units will fund work programs across Murmac, Sun Dog, and the Strike property, with the remaining funds allocated to general working capital.

Why Uranium?

The uranium sector has recently experienced strong growth, largely driven by increasing global demand and efforts to diversify from Russian supply chains. On September 30, The New York Times discussed the resurgence in Western uranium production, highlighting that "uranium mines are ramping up across the West, spurred by rising demand for electricity and federal efforts to cut Russia out of the supply chain." Aero Energy's recent discoveries and forthcoming winter drilling plans at Murmac and Sun Dog reflect this trend, with CEO Galen McNamara remarking, "The combination of historical data and the results from the first drill program serve as evidence that basement-hosted mineralization . . . is present in the area," suggesting strong potential for the Canadian uranium market to contribute to non-Russian nuclear fuel supplies.

Jeff Clark of The Gold Advisor highlighted his continued confidence in the company by stating, "I remain overweight the stock."

On October 9, Reuters reported that demand from U.S. buyers has been on the rise, as "a strong rise in demand from its U.S. customers" pushed Orano's recent plans to expand uranium enrichment in the United States and France. This shift underscores Aero Energy's recent investments in Northern Saskatchewan, where the company has identified high-grade uranium mineralization in both the Murmac and Sun Dog projects, aiming to meet future supply demands with a focus on basement-hosted deposits.

As Forbes reported on October 11, the uranium market experienced renewed momentum after Russian President Vladimir Putin hinted at the possibility of a ban on uranium exports to Western nations. This suggestion "jolted the uranium market," which had been declining after peaking earlier in the year. The price of uranium rebounded to US$83.50 per pound, reflecting rising concerns about potential supply disruptions. Citi analysts noted that “Russia supplies close to 12% of U3O8, 25% of UF6, and 35% of EUP to international markets,” underscoring the challenges that Western nations, particularly the U.S. and Europe, could face in replacing these critical materials. This market dynamic positions uranium companies operating outside of Russia, like those in the Athabasca Basin, to benefit from supply gaps and heightened demand.

MSN reported on October 13 that the UK's nuclear power capacity is set to decrease dramatically in the coming years, with the planned closure of four out of five remaining nuclear plants by 2028. This reduction in capacity is expected to increase pressure on global uranium supplies as demand for nuclear energy continues to rise amid efforts to meet climate goals. The ongoing shift toward low-carbon energy sources, coupled with the planned closures, could create further supply constraints and drive demand for uranium from alternative sources.

Aero's Catalysts

According to the company's October 2024 investor presentation, the ongoing development at Murmac and Sun Dog highlights Aero Energy's strategy to enhance shareholder value by targeting high-grade uranium deposits in underexplored regions. Aero has leveraged recent technology investments, including VTEM Plus aerial surveys, which identified graphite-rich formations favorable for uranium. The exploration efforts build on the CA$7.6 million previously invested by project partners Fortune Bay and Standard Uranium, which has contributed to refining the drill targets. As Aero works with its partners to maximize the impact of this winter's drilling program, the company's strategic location on the north rim of the Athabasca Basin positions it well to expand these discoveries and attract continued investor interest.

The recently announced CA$2.5 million private placement will further strengthen Aero's financial capacity to carry out its targeted drill campaigns and exploration work.

Analyzing Aero

Jeff Clark of The Gold Advisor, in his October 17 update, noted that Aero Energy has "identified more than 70 kilometers of strike to test for high-grade basement-hosted uranium," emphasizing the company's significant exploration potential in a region known for some of the world's richest uranium deposits.

Clark further commented on Aero Energy's recent results, underscoring the importance of drill hole M24-017, which intersected 8.4 meters of uranium mineralization, grading 0.3% U3O8, with assays reaching as high as 13.8% U3O8. He stated, "While not a discovery hole, per se, this hole underscores the company's thesis that these two projects are prospective for the same type of uranium mineralization as Arrow and Triple R." This observation reinforces Aero Energy's exploration model, which targets basement-hosted uranium deposits similar to those found at other significant Athabasca Basin discoveries. [OWNERSHIP_CHART-11173]

Additionally, Clark expressed optimism regarding Aero Energy's current valuation and future prospects, recommending it as a strong buy at current levels. He highlighted his continued confidence in the company by stating, "I remain overweight the stock," suggesting that Aero Energy presents a compelling opportunity for speculative investors in the uranium exploration space.

The recently announced CA$2.5 million private placement was also acknowledged by Clark as a necessary step to fund further exploration activities. While he expressed some caution about potential dilution, he affirmed his overall support for the financing, noting that "its projects are very much worthy of follow-up."

Ownership and Share Structure

According to Refinitiv, management and insiders own 3.11% of Aero Energy. Of those, CEO Galen McNamara has the most at 2.97%. Institutions owns 4.79% with MMCAP Asset Management holding 3.89%. The rest is retail.

Aero has 92.3 million free float shares and a market cap of CA$4.5 million. The 52 week range is CA$0.040–$0.26.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1) James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.

2) This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: AERO:TSXV;AAUGF:OTC;UU3:FRA, )

Full Text:

Scientists have recovered the first genetic data from an extinct bird in the Caribbean, thanks to the remarkably preserved bones of a Creighton's caracara in a flooded sinkhole on Great Abaco Island in the Bahamas. Studies of ancient DNA from tropical birds have faced two formidable obstacles. Organic material quickly degrades when exposed to heat, light and oxygen. And birds' lightweight, hollow bones break easily, accelerating the decay of the DNA within. But the dark, oxygen-free depths of a 100-foot blue hole known as Sawmill Sink provided ideal preservation conditions for the bones of Caracara creightoni, a species of large carrion-eating falcon that disappeared soon after humans arrived in the Bahamas about 1,000 years ago. Florida Museum of Natural History researcher Jessica Oswald and her colleagues extracted and sequenced genetic material from the 2,500-year-old C. creightoni femur. Because ancient DNA is often fragmented or missing, the team had modest expectations for what they would find –- maybe one or two genes. But instead, the bone yielded 98.7% of the bird's mitochondrial genome, the DNA most living things inherit from their mothers. The mitochondrial genome showed that C. creightoni is closely related to the two remaining caracara species alive today: the crested caracara and the southern caracara. The three species last shared a common ancestor between 1.2 and 0.4 million years ago. "This project enhanced our understanding of the ecological and evolutionary implications of extinction, forged strong international partnerships, and trained the next generation of researchers," says Jessica Robin, a program director in National Science Foundation's Office of International Science and Engineering, which funded the study.

Image credit: Florida Museum photo by Kristen Grace

Emerita Resources Corp. (EMO:TSX.V; EMOTF:OTCQB; LLJA:FSE) announces results from a metallurgical testing program at its wholly-owned Iberian Belt West (IBW) project in Spain. Read why one expert says the company is in "the right place to be."

Hercules Metals Corp. (BADEF:OTCMKTS; BIG:TSXV) has announced advancements in its exploration efforts at the western Idaho Leviathan porphyry copper system. Read more about the significant shallow mineralization discoveries and new target areas that could indicate further resource potential.

Aero Energy Ltd. (AERO:TSXV; AAUGF:OTC; UU3:FRA) has announced significant advancements at its Murmac and Sun Dog uranium projects in Northern Saskatchewan. Read how this and a CA$2.5-million non-brokered private placement aim the company towards further exploration.

Halima Aden attends the premiere of Netflix's Travis Scott: Look Mom I Can Fly at Barker Hangar on Aug. 27, 2019, in Santa Monica, Calif.; Credit: Rich Fury/Getty Images

For Halima Aden, the decision to walk away from a career as the world's first hijab-wearing supermodel was fairly clear cut. She's felt used for so long, she says — by the modeling industry and by UNICEF, the organization she was photographed by as a child in a refugee camp in Kenya and later served as an ambassador for.

Aden has been featured on the covers of Vogue, Elle and Allure magazines. And she walked the runway for Rihanna's Fenty Beauty and Kanye West's Yeezy.

She tells Morning Edition host Rachel Martin she wanted to be a role model for young girls while being true to herself, but she wasn't accomplishing either. Modeling, she realized, was in "direct conflict" with who she is.

"I'm not a cover girl, I'm Halima from Kakuma," she says. "I want to be the reason why girls have confidence within themselves, not the reason for their insecurity."

Aden was raised in the Kakuma refugee camp in northwestern Kenya. She and her family moved to Minnesota in 2004 when she was 7.

It was there her journey as a model began, competing for Miss Minnesota USA in 2016, seeking a scholarship. She finished in the semifinals, and says from there, modeling "fell from the sky" into her lap.

Interview Highlights

You saw [modeling] not just as a chance to wear gorgeous clothes and to have your photo in magazines but also as a way to help people.

Growing up in America, not seeing representation, not seeing anybody who dressed like me look like me, it did make me feel like, wow, what's wrong with me, you know? And I'm sure if I had if I would have had representation growing up, I would have been so much more confident to wear my hijab, to be myself, to be authentic. But to be that person, to grow up and be on the cover of magazines, I've covered everything from Vogue to Allure, some of the biggest publications in fashion. And yet I still couldn't relate personally to my own image because that's not who I really am. That's not how I really dress. That's not how my hijab really looks. And, you know, fashion, it can be a very creative field, and I completely appreciate that. But my hijab was just getting spread so thin that I knew I had to give it all away, give it up. I'm not a cover girl. I am Halima from Kakuma. I want to be the reason why girls have confidence within themselves, not the reason for their insecurity.

When you say your hijab was being kind of styled out of existence, what passed for a hijab as you were walking down those runways?

Everything. Oh, my goodness. I had jeans at one point on my head as a hijab. I had Gucci pants styled as a turban. It just didn't even make sense, and I felt so far removed from the image itself.

During the pandemic you decided to walk away from fashion and UNICEF. Was it a complicated decision?

I'll be honest with you, the feelings that I've had towards the fashion industry and UNICEF, it was just multiplying as the years went on, so it was just festering. You know, because the fashion industry is very known to use these young girls and boys while their young, age 14 to like 24, I think is the average career of a model. And then they just replace them and move on to a newer model. And same with UNICEF. They've been photographing me and using me since the time I was a baby in a refugee camp. I remember getting those headshots taken and it made me feel, it's very dehumanizing. And so I wanted to show UNICEF, too. How does it feel to be used? It's not a good feeling. And so let's stop using people.

What are you going to do [next]?

For me right now, I don't know what's next. And that's OK. That's OK, because I'm young and I have time to figure it out. And I'm grateful. I'm grateful to the people that I've met. I'm grateful to the agents that I worked with. I'm grateful for the experiences I was able to have these last four years. But at the same time, I just am also grateful that I don't have to do that anymore because it was in direct conflict with who I am as an individual, as a human being.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Washington State Department of Agriculture entomologist Chris Looney displays a dead Asian giant hornet, a sample sent from Japan and brought in for research last year in Blaine, Wash.; Credit: Elaine Thompson /AFP via Getty Images

Murder hornets. They're back.

Authorities in Washington state have announced that they've confirmed the first U.S. report this year of an Asian giant hornet, or Vespa mandarinia, in a town north of Seattle.

"Basically the only information we have is that a slightly dried out, dead specimen was collected off of a lawn in Marysville," said Sven Spichiger, managing entomologist with the state agriculture department, during a press conference.

"There really isn't even enough information to speculate on how it got there or how long it had been there," Spichiger added.

Because of its withered condition and the fact that male giant hornets don't typically emerge until July, agriculture officials believe the hornet discovered in early June was likely from a previous season and just recently found.

So-called "murder hornets" are native to Asia but have been spotted in Washington state and Canada over the past two years. The sting of the Vespa mandarinia can be life-threatening to humans, and the killer insects are known to wipe out the colonies of their fellow bugs, particularly honey bees.

According to genetic testing of the specimen discovered in Washington this month, the dead hornet was not the same as the other giant hornets discovered in North America since 2019. The hornet's coloration, which indicates it came from southern Asia, also suggested it arrived in "probably a separate event" than the ones previously known, Spichiger said.

But he emphasized that that was not necessarily cause for alarm.

"I want to very much clarify that a single dead specimen does not indicate a population," Spichiger said.

Washington agriculture officials are now setting murder hornet traps in the area of the discovery and are encouraging "citizen scientists" to do the same.

This content is from Southern California Public Radio. View the original story at SCPR.org.

When a promising new drug to treat obesity was approved by the Food and Drug Administration for sale in the U.S. last month, it was the first such treatment to gain approval since 2014.

In clinical trials, weekly injections of semaglutide — or Wegovy, as it's been branded -- helped people drop an average of 15% of their body weight. That's an average of about 34 pounds over 16 months, before their weight plateaued, a far greater weight loss, obesity specialists say, than achieved with other drugs on the market. At least as important, Wegovy raised none of the alarm bells with the FDA or obesity doctors that it might trigger serious side effects of the sort experienced by some people taking fen-phen or some previous medical treatments for obesity.

But with a price tag for Wegovy of $1,000 to $1,500 a month, a very big question remains: Will insurers cover its significant cost for the many millions of people like Marleen Greenleaf, who might benefit?

Greenleaf grew up on the island of Trinidad, where her entire family paid little heed to what they ate and paid a high medical price, she says: "My husband has diabetes, my sister has diabetes, my brother has diabetes."

Since then, she's tried — and failed — at numerous diets, says Greenleaf, now 58 and an administrator at a charter school in Washington, D.C. Then, in 2018, she signed up for the clinical trial of a new drug — a once-weekly shot that changes the way her brain signals hunger.

A drug that finally stops her cravings

She noticed the change soon after her first injection of Wegovy: "For me, there was something that triggered in my brain to tell me that I was not hungry," she says. No more fierce cravings for the chocolate chip cookies she adores. Without the cravings she was able to slow down and reconsider the foods she'd been reaching for.

"I also wanted to eat healthier," she says. "I was looking at options, reading labels, looking at the calories — not just the calories, but also the sugar."

Over the 68-week research trial, Greenleaf dropped 40 pounds. Her blood pressure fell, which meant she qualified to donate her kidney to her husband, who was on dialysis.

"It was one of the best gifts of life that I could have ever given," she says.

But after that study ended, Greenleaf regained some of the weight. Wegovy is considered a long-term, possibly lifelong medication to treat chronic obesity. In the pre-marketing clinical studies, weight loss topped out at a total average weight loss of 15-18%, even as people continued to take the drug. And, as was the case with Greenleaf, once they stopped getting the weekly injections some of that weight came back.

Now, Greenleaf wants to resume the Wegovy shots.

"My only challenge actually is getting the insurance company to approve it," she says.

Reimbursement for obesity drugs' cost is patchy

Insurance coverage, it turns out, is a giant question — not just with Wegovy, but with obesity drugs in general. Some private insurers do include some prescription obesity drugs in the list of medicines they'll cover; it's too early to tell whether Wegovy will make those lists. Many doctors and patients are optimistic, because it is a higher dose of an existing diabetes medication called Ozempic, which is often covered by insurers.

A few select state Medicaid programs will cover medications that treat obesity, in some circumstances. But, significantly, Medicare does not cover obesity drugs — and many private insurers typically follow Medicare's lead.

Yet the demand for a good treatment is there, says Dr. Fatima Cody Stanford, a leading obesity researcher at Harvard. She was not involved in conducting the Wegovy clinical trial, but closely followed it. "I'm excited about it," she says, because of the dramatic weight loss.

The drug acts on the brain so people eat less and store less of what they eat. That helps address the excess weight as well as helping with numerous related diseases of the liver or heart, for example.

Why the FDA has been slow to approve obesity treatments

There is a long history of drugs that have looked like promising treatments for obesity, then failed. Decades ago, amphetamines, were prescribed, until their addictive properties became apparent. In the 1990s, the combination of fenfluramine and phentermine — administered as the diet drug fen-phen — was heavily marketed, only to later be pulled from the market for causing heart valve problems.

Those experiences and others have made physicians skeptical.

"In obesity medicine field, we've learned to be cautiously optimistic each time we have a new medication that looks promising," says Dr. Ihuoma Eneli, director of the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital in Columbus, Ohio, who was not involved in the study of Wegovy.

So far, Eneli does not see any obvious concerns with the class of drugs that includes Wegovy, and calls the results so far "very promising." Wegovy is similar to another drug made by Novo Nordisk — Saxenda — which has been on the market since 2014, and which Eneli occasionally prescribes to her pediatric patients who are struggling with obesity.

In clinical research studies, the primary side effects reported after taking Wegovy affected the digestive system: nausea, diarrhea, vomiting, constipation, abdominal pain or intestinal infections.

Eneli says such side effects and their frequency are milder than the problems that have arisen in the past. That good safety profile may mean the drug is "less likely to come up with unanticipated risks," she says.

But, the new drug will be of little use, she and other doctors who treat obesity say, if it's not also affordable for patients.

"Before I even bring up that drug with my patients, I'm looking to see which insurance they are having on the left side of my screen — because that will determine whether I bring it up," Stanford, the Harvard physician, says. "If it's out of reach, like I said, I won't bring it up."

Stanford says her patients on existing obesity medications do extraordinary things to keep their coverage so they can afford to stay on the drugs.

"Several nurses here at the hospital that are my patients stayed working — they were supposed to retire — so they could stay on their injectable medication," Stanford says,"because that's how beneficial it was to them."

Why some are willing to pay out of pocket

Some people, like David Scheesley, 42, says he would consider paying for Wegovy, even if he had to pay the full sticker price. The Hanford, Calif., correctional officer has tried since 2019 to lose weight on various diets — low-fat, all-meat, all-vegetable — without success. His weight has led to other health concerns — with his blood fats and his heart — which makes Scheesley think of his 5-year-old son.

"I want to see him for a lot of years; I don't want to have a stroke," he says. "I don't want to have diabetes. I want to be there for him. So, for me personally, that [monetary cost] is not astronomical, if it can give me some more time."

Novo Nordisk, the company that makes Wegovy, is in talks with insurers, and acknowledges that ensuring health insurance coverage of its drug is critical. The challenge, says Douglas Langa, executive vice president of Novo Nordisk North America, is getting doctors, patients, and politicians to recognize obesity as a disease — and that therefore insurance should cover the cost of medicine to treat it.

"There's a medical component to [obesity] that needs to be recognized; this is a disease state like we should be treating any other disease state," Langa says. He says about 40% of private insurers cover Saxenda, the similar weight-loss medication the company makes.

Langa tells insurance companies this, making the case for why prescriptions for Wegovy should be covered. His company is also heavily lobbying Congress to pass legislation to allow Medicare to cover obesity medications. It makes sense from a financial perspective, he argues, because obesity is the root disease underlying so many other diseases.

"We do believe insurers understand that [untreated obesity] is a gateway into 60 other health conditions," Langa says. The need is hard to ignore, he adds. More than 100 million people in the U.S. alone struggle with obesity.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Racial and ethnic minorities tend to receive lower-quality health care than whites do, even when insurance status, income, age, and severity of conditions are comparable.